Placebo + standard of care

DRUG2 trials

Sponsors

Novartis Pharmaceuticals, Yale University

Conditions

Focal Segmental GlomerulosclerosisLupus Nephritis

Phase 1

AMPK-activation by Metformin in FSGS: AMP-FSGS

RecruitingNCT06090227

Yale UniversityFocal Segmental Glomerulosclerosis

Start: 2023-12-14End: 2027-11-01Target: 30Updated: 2026-02-03

Phase 2

Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

RecruitingNCT05268289

Novartis PharmaceuticalsLupus Nephritis

Start: 2022-08-10End: 2028-09-28Target: 240Updated: 2026-07-30